Can Plant-Made Copper Chaperone for Superoxide Dismutase Heal Early Alzheimer's Disease?
Nonfiction, Health & Well Being, Medical
| Author: | Bernd Kastenholz | ISBN: | 9783656313885 |
| Publisher: | GRIN Verlag | Publication: | November 19, 2012 |
| Imprint: | GRIN Verlag | Language: | English |
| Author: | Bernd Kastenholz |
| ISBN: | 9783656313885 |
| Publisher: | GRIN Verlag |
| Publication: | November 19, 2012 |
| Imprint: | GRIN Verlag |
| Language: | English |
Commercially available medicinal plant extracts such as Ginkgo biloba leaf extract show no consistent pattern of clinical benefit for people with dementia or cognitive impairment, and have been suggested to be toxic to cells at higher doses. However, medicinal plants may contain other more efficient bioactive molecules apart from the well-known flavonoids and terpenoids. Therapeutic recombinant proteins, plant-made copper chaperone for superoxide dismutase (CCS) derived from Ginkgo biloba leaves, may establish and maintain physiologic Cu levels through restoration and modulation of biometal metabolism in organ systems of younger Alzheimer patients (> 50 years). Medications developed from plant-made copper chaperone proteins may delay progression during early disease stages or even be a basis for a possible causal treatment of preclinical stages of Alzheimer's disease by preventing formation of A ? plaques in the brain, a major putative factor involved in Alzheimer's disease etiopathogenesis.
Commercially available medicinal plant extracts such as Ginkgo biloba leaf extract show no consistent pattern of clinical benefit for people with dementia or cognitive impairment, and have been suggested to be toxic to cells at higher doses. However, medicinal plants may contain other more efficient bioactive molecules apart from the well-known flavonoids and terpenoids. Therapeutic recombinant proteins, plant-made copper chaperone for superoxide dismutase (CCS) derived from Ginkgo biloba leaves, may establish and maintain physiologic Cu levels through restoration and modulation of biometal metabolism in organ systems of younger Alzheimer patients (> 50 years). Medications developed from plant-made copper chaperone proteins may delay progression during early disease stages or even be a basis for a possible causal treatment of preclinical stages of Alzheimer's disease by preventing formation of A ? plaques in the brain, a major putative factor involved in Alzheimer's disease etiopathogenesis.
